Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030466 | 0.91 | PDK1 (0.64) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL1031108 | 0.90 | PDK1 (0.54) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL1032097 | 0.90 | RAB9A (0.56) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL1031919 | 0.83 | RAB9A (0.57) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL1506733 | 0.83 | RAB9A (0.57) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL1031917 | 0.83 | RAB9A (0.57) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL1032199 | 0.81 | PDK1 (0.65) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| Bromide SCHEMBL3055052 | 0.80 | PDK1 (0.64) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL3537070 | 0.78 | PDK1 (0.61) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL13314813 | 0.78 | PDK1 (0.61) | PDK1RAB9ASMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2289885-A1 | Intermediates for the preparation of pramipexole | Dipharma Francis S.r.l. (IT) | 2011-03-02 | — | — | EP | claimed |
| US-20070191439-A1 | Intermediates for the preparation of pramipexole | DIPHARMA S.P.A. (IT) | 2007-08-16 | — | — | US | claimed |
| EP-1730129-A2 | INTERMEDIATES FOR THE PREPARATION OF PRAMIPEXOLE | Dipharma S.p.A. (IT) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092871-A2 | INTERMEDIATES FOR THE PREPARATION OF PRAMIPEXOLE | DIPHARMA S.P.A. (IT) | 2005-10-06 | — | — | WO | claimed |
| US-20120253047-A1 | PROCESS FOR THE PREPARATION OF (R)-PRAMIPEXOLE | DIPHARMA S.P.A. (IT) | 2012-10-04 | — | — | US | disclosed |
| US-8203002-B2 | Intermediates for the preparation of pramipexole | DIPHARMA S.P.A. (IT) | 2012-06-19 | — | — | US | disclosed |
| EP-2289885-A1 | Intermediates for the preparation of pramipexole | Dipharma Francis S.r.l. (IT) | 2011-03-02 | — | — | EP | disclosed |
| EP-1730129-B1 | INTERMEDIATES FOR THE PREPARATION OF PRAMIPEXOLE | DIPHARMA FRANCIS SRL (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-20100222595-A1 | INTERMEDIATES FOR THE PREPARATION OF PRAMIPEXOLE | DIPHARMA S.P.A. (IT) | 2010-09-02 | — | — | US | disclosed |
| US-7741490-B2 | Intermediates for the preparation of pramipexole | DIPHARMA S.P.A. (IT) | 2010-06-22 | — | — | US | disclosed |
| US-20070191439-A1 | Intermediates for the preparation of pramipexole | DIPHARMA S.P.A. (IT) | 2007-08-16 | — | — | US | disclosed |
| EP-1730129-A2 | INTERMEDIATES FOR THE PREPARATION OF PRAMIPEXOLE | Dipharma S.p.A. (IT) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092871-A2 | INTERMEDIATES FOR THE PREPARATION OF PRAMIPEXOLE | DIPHARMA S.P.A. (IT) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222595-A1 | INTERMEDIATES FOR THE PREPARATION OF PRAMIPEXOLE | CYP11B2, CYP11B1, CYP4A11 | PDK1 288/4885RAB9A 3119/4885SMN1; SMN2 1155/4885 |
| US-20120253047-A1 | PROCESS FOR THE PREPARATION OF (R)-PRAMIPEXOLE | DPP4, DNPEP, PNMT | PDK1 2120/4885RAB9A 1726/4885SMN1; SMN2 1054/4885 |
| US-20070191439-A1 | Intermediates for the preparation of pramipexole | CYP11B2, CYP11B1, CYP4A11 | PDK1 288/4885RAB9A 3119/4885SMN1; SMN2 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.